Daniel Bellm
Former Member
Thumbnail Image
Last Name
Bellm
First name
Daniel
Phone
+41 71 224 7269

Filters

2
2
Reset filters

Settings
Now showing 1 - 2 of 2
  • Publication
    The Future of Pharmaceutical Manufacturing
    (Springer, 2014)
    Basu, Prabir K.
    ;
    Friedli, Thomas
    ;
    Bellm, Daniel
    ;
    Friedli, Thomas
    ;
    Basu, Prabir K.
    ;
    Bellm, Daniel
    ;
    Werani, Jürgen
    The pharmaceutical industry is definitely a high-tech industry, for its role in discovery of new medicines for the treatment of unmet medical needs. Pharmaceutical manufacturing is complex and sophisticated due to various reasons, but in its current state probably cannot be categorized as really high-tech, too. In fact, pharmaceutical manufacturing was considered as relatively low-tech even by the pharmaceutical companies themselves as recently as in 2002. When ex-FDA commissioner Mark McClellan sought a benchmark for future pharmaceutical manufacturing performance, he looked outside the industry, and challenged Pharma, "You need to improve…Other high-tech industries have achieved enormous productivity gains in manufacturing in the last 25 years. We should expect nothing less from the Pharmaceutical industry."
    Type: book section
    DOI: 10.1007/978-3-642-35161-7_29
    URI: https://www.alexandria.unisg.ch/handle/20.500.14171/87498
    Scopus© Citations 2
  • Publication
    Introduction to Leading Operational Excellence: Making OPEX a Competitive Weapon
    (Springer Berlin Heidelberg, 2013)
    Friedli, Thomas
    ;
    Basu, Prabir K.
    ;
    Friedli, Thomas
    ;
    Basu, Prabir K.
    ;
    Bellm, Daniel
    ;
    Werani, Jürgen
    In our second book on Operational Excellence in the Pharmaceutical Industry titled "The Pathway to Operational Excellence", published in 2010, we had undertaken an imaginary journey to develop the framework and structure of the book. It gave us the opportunity to describe our experiences from working with dozens of different pharmaceutical manufacturers in the US and Europe. We suggested a sequence starting with preparing for the journey and finishing with the re-definition of the destination leading to the selection of the next destination so that the journey will be an on-going one. Two years later, we have decided to write another book. The main reason for doing this is the positive feedback we have received on the first two books. The other reason is our conviction that despite the renewed enthusiasm for outsourcing in the industry, manufacturing will remain a critical activity for every major pharmaceutical company, and the continuous improvement of manufacturing will not just be an option, but a necessity.
    Type: book section
    DOI: 10.1007/978-3-642-35161-7_1
    URI: https://www.alexandria.unisg.ch/handle/20.500.14171/90018
    Scopus© Citations 1